4:06 PM ET
8-K
Court & Legal Update
Regenxbio Court & Legal Update
REGENXBIO and UPenn entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve all patent infringement litigation regarding U.S. Patent Nos. 10,526,617 and 11,680,274. Sarepta will pay REGENXBIO $39.0 million and receive a covenant not to sue for future claims relating to gene therapy products using an AAVrh74-based capsid, including ELEVIDYS.
- Counterparty
- Sarepta Therapeutics, Inc.